Endothelial Dysfunction in Breast Cancer Survivors on Aromatase Inhibitors: Changes over Time

Conclusion Endovascular dysfunction is an early sign for atherosclerosis and vascular impairment. This study suggests that postmenopausal breast cancer survivors on aromatase inhibitor therapy develop endothelial dysfunction as early as six months which is a predictor of adverse CV disease. We hypothesize that long-term use of AIs can lead to persistent endothelial dysfunction. It is unclear if these changes are reversible once AI use is discontinued and further investigation is necessary.PMID:37066265 | PMC:PMC10104271 | DOI:10.21203/rs.3.rs-2758909/v1

Source: Atherosclerosis - April 17, 2023 Category: Cardiology Authors: Adnan Shaaban Ashley Petersen Heather Beckwith Natalia Florea David A Potter Douglas Yee Rachel I Vogel Daniel Duprez Anne H Blaes Source Type: research